FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Barbara Clayman

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Procedures

Concepts & Ideas

Geographic Areas

Costa Rica

Anatomy

Capsid

Co-author Network

Publications

TOP 3
Raphael P Viscidi; Barbara Clayman
Serological cross reactivity between polyomavirus capsids.
Raphael P Viscidi; Brad Snyder; Susan Cu-Uvin; Joseph W Hogan; Barbara Clayman; Robert S Klein; Jack D Sobel; Keerti V Shah
Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women.
Sophia S Wang; Mark Schiffman; Rolando Herrero; Joseph D Carreon; Allan Hildesheim; Ana Cecilia Rodriguez; M Concepcion Bratti; Mark E Sherman; Jorge Morales; Diego Guillen; Mario Alfaro; Barbara Clayman; Robert D Burk; Raphael P Viscidi
Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Barbara Clayman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Raphael P Viscidi; Barbara Clayman
Serological cross reactivity between polyomavirus capsids.
Advances in experimental medicine and biology 2006;577():73-84.
2005: Raphael P Viscidi; Brad Snyder; Susan Cu-Uvin; Joseph W Hogan; Barbara Clayman; Robert S Klein; Jack D Sobel; Keerti V Shah
Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(1):283-8.
2004: Sophia S Wang; Mark Schiffman; Rolando Herrero; Joseph D Carreon; Allan Hildesheim; Ana Cecilia Rodriguez; M Concepcion Bratti; Mark E Sherman; Jorge Morales; Diego Guillen; Mario Alfaro; Barbara Clayman; Robert D Burk; Raphael P Viscidi
Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica.
British journal of cancer 2004;91(7):1269-74.
2004: Raphael P Viscidi; Mark Schiffman; Allan Hildesheim; Rolando Herrero; Philip E Castle; M Concepcion Bratti; Ana Cecilia Rodriguez; Mark E Sherman; Sophia Wang; Barbara Clayman; Robert D Burk
Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004;13(2):324-7.
2003: Raphael P Viscidi; Linda Ahdieh-Grant; Michael F Schneider; Barbara Clayman; L Stewart Massad; Kathryn Anastos; Robert D Burk; Howard Minkoff; Joel Palefsky; Alexandra M Levine; Howard D Strickler
Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.
The Journal of infectious diseases 2003;188(12):1834-44.
2003: Sophia S Wang; Mark Schiffman; Tammy Shields; Rolando Herrero; Allan Hildesheim; M Concepcion Bratti; Mark E Sherman; Ana Cecilia Rodriguez; Philip E Castle; Jorge Morales; Mario Alfaro; T Wright; S Chen; Barbara Clayman; Robert D Burk; Raphael P Viscidi
Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.
British journal of cancer 2003;89(7):1248-54.
2003: Raphael P Viscidi; Dana E Rollison; Emma Viscidi; Barbara Clayman; Elizabeth Rubalcaba; Richard Daniel; Eugene O Major; Keerti V Shah
Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays.
Clinical and diagnostic laboratory immunology 2003;10(2):278-85.
2003: Raphael P Viscidi; Linda Ahdieh-Grant; Barbara Clayman; Kelly Fox; L Stewart Massad; Susan Cu-Uvin; Keerti V Shah; Kathryn Anastos; Kathleen E Squires; Ann Duerr; Denise J Jamieson; Robert D Burk; Robert S Klein; Howard Minkoff; Joel Palefsky; Howard D Strickler; Paula Schuman; Eva Piessens; Paolo Miotti
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.
The Journal of infectious diseases 2003;187(2):194-205.
1999: Y Sun; José Eluf-Neto; F X Bosch; N Muñoz; Jan M M Walboomers; C J Meijer; Keerti V Shah; Barbara Clayman; Raphael P Viscidi
Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1999;8(10):935-40.
1999: Howard D Strickler; Raphael P Viscidi; Carlos Escoffery; Carole Rattray; Karen L Kotloff; J Goldberg; Angela Manns; Charles S Rabkin; R Daniel; Barrie Hanchard; C Brown; M Hutchinson; D Zanizer; Joel Palefsky; Robert D Burk; Beverley Cranston; Barbara Clayman; Keerti V Shah
Adeno-associated virus and development of cervical neoplasia.
Journal of medical virology 1999;59(1):60-5.
1998: Howard D Strickler; M H Schiffman; Keerti V Shah; charles rabkin; J T Schiller; S Wacholder; Barbara Clayman; Raphael P Viscidi
A survey of human papillomavirus 16 antibodies in patients with epithelial cancers.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 1998;7(4):305-13.
1997: John S Lambert; Raphael P Viscidi; M C Walker; Barbara Clayman; M Winget; Mark Wolff; David H Schwartz
Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
Clinical and diagnostic laboratory immunology 1997;4(3):302-8.
1997: Raphael P Viscidi; Karen L Kotloff; Barbara Clayman; Karin G Russ; S Shapiro; Keerti V Shah
Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.
Clinical and diagnostic laboratory immunology 1997;4(2):122-6.
1993: A Funkhouser; M L Clements; S Slome; Barbara Clayman; Raphael P Viscidi
Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients.
AIDS research and human retroviruses 1993;9(7):627-32.
1991: J S Kinney; J H Conway; M W Hilgartner; Barbara Clayman; K Mayur; Robert H Yolken; Raphael P Viscidi
Humoral immune responses to gag and env proteins from human immunodeficiency virus type 1 in hemophiliac patients.
American journal of hematology 1991;36(1):35-41.
1990: Raphael P Viscidi; E Ellerbeck; L Garrison; K Midthun; M L Clements; Barbara Clayman; B Fernie; G Smith
Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
AIDS research and human retroviruses 1990;6(11):1251-6.